Patent · US Active

Pluripotent stem cell and T cell differentiated therefrom and application thereof

US11299709B2 · kind B2 · utility

0Cited by

1References

10Claims

0Family size

Assignee

Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences · CN

Inventors

Jinyong Wang · Nanjing, CN
Rongqun Guo · Tangxia, CN
Mengyun Zhang · Bositenghu, CN
Lijuan Liu · San Jose, US
Xiaofei LIU · Xuzhou, CN
Cui Lv · 流花街道, CN
Juan Du · Shanghai, CN

Key dates

Filing date	Jan 11, 2018
Grant date	Apr 12, 2022
Priority date	—
Expiry date	Aug 8, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2510/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a pluripotent stem cell comprising a co-expression vector in which Runx1 and Hoxa9 are of in tandem, and a T cell differentiated therefrom and application thereof. In the present invention, Pluripotent stem cells inducibly co-expressing exogenous Runx1 and Hoxa9 are successfully established by introducing an exogenous vector co-expressing Runx1 and Hoxa9 into pluripotent stem cells. The pluripotent stem cells are directionally differentiated into T-lineage progenitor cells and will be developed into T cells. The pluripotent stem cell-derived T cells obtained by the method of the present invention are not only functionally normal but also have no tumorigenic risk.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.